In:
Cancer, Wiley, Vol. 124, No. 14 ( 2018-07-15), p. 2956-2963
Abstract:
Clinical trials have demonstrated that patients with chronic‐phase chronic myeloid leukemia with deep and durable molecular responses can attempt to stop using tyrosine kinase inhibitors. The French Chronic Myeloid Leukemia Study Group (France Intergroupe des Leucémies Myéloïdes Chroniques) has developed recommendations for tyrosine kinase inhibitor discontinuation in daily practice.
Type of Medium:
Online Resource
ISSN:
0008-543X
,
1097-0142
DOI:
10.1002/cncr.v124.14
Language:
English
Publisher:
Wiley
Publication Date:
2018
detail.hit.zdb_id:
1479932-7
detail.hit.zdb_id:
2599218-1
detail.hit.zdb_id:
2594979-2
detail.hit.zdb_id:
1429-1